デフォルト表紙
市場調査レポート
商品コード
601947

糖尿病性胃不全麻痺(DGp)- 疫学予測 2030年

Diabetic Gastroparesis (DGp) - Epidemiology Forecast - 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 90 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.93円
糖尿病性胃不全麻痺(DGp)- 疫学予測 2030年
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 90 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の糖尿病性胃不全麻痺(DGp)の2017年の有病数は1,284万3,848人と推計されています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン)の糖尿病性胃不全麻痺(DGp)市場を調査し、市場および疾患の概要、全体および国別の疫学的予測、性別・臨床タイプ・年齢別の有病数および診断数の推移と予測などについてまとめています。

目次

第1章 重要な洞察

第2章 エグゼクティブサマリー

第3章 方法論

第4章 糖尿病性胃不全麻痺(DGp):患者概要

  • 患者の分布(実数値)
  • 患者の分布(予測値)

第5章 疾病背景と概要

  • イントロダクション
  • 病因と危険因子
  • 徴候と症状
  • 糖尿病性胃不全麻痺(DGp)の病因
  • 診断
    • 臨床スコアリングシステム
    • 糖尿病性胃不全麻痺(DGp)の鑑別診断

第6章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国の総患者数

第7章 糖尿病性胃不全麻痺(DGp)の疫学予測:国別

  • 米国
    • 仮定と根拠
    • 糖尿病性胃不全麻痺(DGp)の総有病数
    • 胃不全麻痺の有病数:糖尿病タイプ別
    • 糖尿病性胃不全麻痺(DGp)の有病数:性別
    • 糖尿病性胃不全麻痺(DGp)の有病数:症状別
  • 欧州5カ国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第8章 糖尿病性胃不全麻痺(DGp)の治療と管理

  • 糖尿病性胃不全麻痺(DGp)の臨床管理におけるコンセンサスガイドライン
  • 糖尿病性胃不全麻痺の管理のためのアルゴリズム
  • ペイシェントジャーニー

第9章 付録

  • 書誌
  • 報告方法

第10章 DelveInsightのサービス内容

第11章 免責事項

第12章 DelveInsightについて

図表

List of Tables

  • Table 1: Prevalent Patient Population of Diabetic Gastroparesis in 7MM (2017-2030)
  • Table 2: Total Prevalent Cases of Diabetic Gastroparesis in the United States (2017-2030)
  • Table 3: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the US (2017-2030)
  • Table 4: Prevalence of Diabetic Gastroparesis based on Gender in the United States (2017-2030)
  • Table 5: Prevalence of Symptoms associated with DGp in the United States (2017-2030)
  • Table 6: Total Prevalent Cases of Diabetic Gastroparesis in Germany (2017-2030)
  • Table 7: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Germany (2017-2030)
  • Table 8: Prevalence of Diabetic Gastroparesis based on Gender in Germany (2017-2030)
  • Table 9: Prevalence of Symptoms associated with DGp in the Germany (2017-2030)
  • Table 10: Total Prevalent Cases of Diabetic Gastroparesis in France (2017-2030)
  • Table 11: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in France (2017-2030)
  • Table 12: Prevalence of Diabetic Gastroparesis based on Gender in France (2017-2030)
  • Table 13: Prevalence of Symptoms associated with DGp in France (2017-2030)
  • Table 14: Total Prevalent Cases of Diabetic Gastroparesis in Italy (2017-2030)
  • Table 15: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Italy (2017-2030)
  • Table 16: Prevalence of Diabetic Gastroparesis based on Gender in Italy (2017-2030)
  • Table 17: Prevalence of Symptoms associated with DGp in Italy (2017-2030)
  • Table 18: Total Prevalent Cases of Diabetic Gastroparesis in Spain (2017-2030)
  • Table 19: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Spain (2017-2030)
  • Table 20: Prevalence of Diabetic Gastroparesis based on Gender in Spain (2017-2030)
  • Table 21: Prevalence of Symptoms associated with DGp in Spain (2017-2030)
  • Table 22: Total Prevalent Cases of Diabetic Gastroparesis in the UK (2017-2030)
  • Table 23: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the UK (2017-2030)
  • Table 24: Prevalence of Diabetic Gastroparesis based on Gender in the UK (2017-2030)
  • Table 25: Prevalence of Symptoms associated with DGp in the UK (2017-2030)
  • Table 26: Total Prevalent Cases of Diabetic Gastroparesis in Japan (2017-2030)
  • Table 27: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Japan (2017-2030)
  • Table 28: Prevalence of Diabetic Gastroparesis based on Gender in Japan (2017-2030)
  • Table 29: Prevalence of Symptoms associated with DGp in Japan (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Glucose and gastric emptying: bidirectional relationship
  • Figure 3: Pathophysiology of diabetic gastroparesis
  • Figure 4: Diagnosis algorithm for Diabetic Gastroparesis
  • Figure 5: Prevalent Patient Population of Diabetic Gastroparesis in 7MM (2017-2030)
  • Figure 6: Total Prevalent Cases of Diabetic Gastroparesis in the United States (2017-2030)
  • Figure 7: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the US (2017-2030)
  • Figure 8: Prevalence of Diabetic Gastroparesis based on Gender in the United States (2017-2030)
  • Figure 9: Prevalence of Symptoms associated with DGp in the United States (2017-2030)
  • Figure 10: Total Prevalent Cases of Diabetic Gastroparesis in the Germany (2017-2030)
  • Figure 11: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Germany (2017-2030)
  • Figure 12: Prevalence of Diabetic Gastroparesis based on Gender in Germany (2017-2030)
  • Figure 13: Prevalence of Symptoms associated with DGp in Germany (2017-2030)
  • Figure 14: Total Prevalent Cases of Diabetic Gastroparesis in France (2017-2030)
  • Figure 15: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in France (2017-2030)
  • Figure 16: Prevalence of Diabetic Gastroparesis based on Gender in France (2017-2030)
  • Figure 17: Prevalence of Symptoms associated with DGp in France (2017-2030)
  • Figure 18: Total Prevalent Cases of Diabetic Gastroparesis in Italy (2017-2030)
  • Figure 19: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Italy (2017-2030)
  • Figure 20: Prevalence of Diabetic Gastroparesis based on Gender in Italy (2017-2030)
  • Figure 21: Prevalence of Symptoms associated with DGp in Italy (2017-2030)
  • Figure 22: Total Prevalent Cases of Diabetic Gastroparesis in Spain (2017-2030)
  • Figure 23: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Spain (2017-2030)
  • Figure 24: Prevalence of Diabetic Gastroparesis based on Gender in Spain (2017-2030)
  • Figure 25: Prevalence of Symptoms associated with DGp in Spain (2017-2030)
  • Figure 26: Total Prevalent Cases of Diabetic Gastroparesis in the UK (2017-2030)
  • Figure 27: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the UK (2017-2030)
  • Figure 28: Prevalence of Diabetic Gastroparesis based on Gender in the UK (2017-2030)
  • Figure 29: Prevalence of Symptoms associated with DGp in the UK (2017-2030)
  • Figure 30: Total Prevalent Cases of Diabetic Gastroparesis in Japan (2017-2030)
  • Figure 31: Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Japan (2017-2030)
  • Figure 32: Prevalence of Diabetic Gastroparesis based on Gender in Japan (2017-2030)
  • Figure 33: Prevalence of Symptoms associated with DGp in Japan (2017-2030)
  • Figure 34: Suggested therapeutic options for gastroparesis
  • Figure 35: Algorithm for the management of diabetic gastroparesis.
  • Figure 36: Patient Journey for DG
  • Figure 37: Unmet Needs of Diabetic Gastroparesis
目次
Product Code: DIEI0274

DelveInsight's 'Diabetic Gastroparesis (DGp)- Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of DGp in the in 7MM covering the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2030

Diabetic Gastroparesis (DGp) - Disease Understanding

The DelveInsight Diabetic Gastroparesis epidemiology report gives the thorough understanding of the DGp by including details such as disease definition, classification, symptoms, risk factors, pathogenesis, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Diabetic Gastroparesis in the 7MM i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The term diabetic gastroparesis (DGp) has been used to describe a serious complication of diabetes resulting in delayed gastric emptying with associated upper gastrointestinal (GI) symptoms in the absence of any mechanical obstruction. Gastroparesis is a disorder affecting people with both type 1 and type 2 diabetes in which the stomach takes too long to empty its contents (delayed gastric emptying).

Diabetic Gastroparesis (DGp) Epidemiology

The Diabetic Gastroparesis (DGp) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major markets. The epidemiology data for Diabetic Gastroparesis epidemiology are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Diabetic Gastroparesis Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases of Diabetic Gastroparesis, prevalence of Gastroparesis associated with types of Diabetes Mellitus, prevalence of Diabetic Gastroparesis based on gender, prevalence of symptoms associated with Diabetic Gastroparesis ) scenario of Sickle Cell Disease(DGp) in the 7MM covering covering the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017-2030.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, Total prevalent population of Diabetic Gastroparesis in 7 MM was observed to be 12,843,848 cases in 2017.

Report Scope

  • The report covers the descriptive overview of Diabetic Gastroparesis, explaining its causes and currently available therapies
  • Comprehensive insight has been provided into the epidemiology of the Diabetic Gastroparesis and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, the UK) & Japan
  • Additionally, an all-inclusive account of both the current and emerging therapies for Diabetic Gastroparesis are provided, along with assessment of the impact new therapies will have on the current treatment landscape
  • A detailed review of global historical and forecasted Diabetic Gastroparesis market is included in the report, covering drug outreach in 7 MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Diabetic Gastroparesis market

Diabetic Gastroparesis Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Diabetic Gastroparesis Epidemiology Segmentation

  • Total prevalent cases of Diabetic Gastroparesis in 7 MM
  • Prevalence of Gastroparesis associated with types of Diabetes Mellitus in 7 MM
  • Prevalence of Diabetic Gastroparesis based on gender in 7 MM
  • Prevalence of symptoms associated with Diabetic Gastroparesis in 7 MM

Table of Contents

1. Key Insights

2. Executive Summary

3. SWOT Analysis for Diabetic Gastroparesis (DGp)

4. Diabetic Gastroparesis Market Overview at a Glance

  • 4.1. Market Share (%) Distribution of Diabetic Gastroparesis in 2017
  • 4.2. Market Share (%) Distribution of Diabetic Gastroparesis in 2030

5. Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Etiology and risk factors
  • 5.3. Signs and Symptoms
  • 5.4. Pathogenesis of Diabetic Gastroparesis
  • 5.5. Diagnosis
    • 5.5.1. Clinical Scoring System
    • 5.5.2. Differential diagnosis of Diabetic Gastroparesis

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. 7MM Total Prevalent Patient Population of Diabetic Gastroparesis

7. Country Wise-Epidemiology of Diabetic Gastroparesis

  • 7.1. The United States
    • 7.1.1. Assumptions and Rationale
    • 7.1.2. Total Prevalent Cases of Diabetic Gastroparesis in the United States
    • 7.1.3. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the United States
    • 7.1.4. Prevalence of Diabetic Gastroparesis based on Gender in the United States
    • 7.1.5. Prevalence of Symptoms associated with DGp in the United States
  • 7.2. EU5
    • 7.2.1. Assumptions and Rationale
  • 7.3. Germany
    • 7.3.1. Total Prevalent Cases of Diabetic Gastroparesis in Germany
    • 7.3.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Germany
    • 7.3.3. Prevalence of Diabetic Gastroparesis based on Gender in Germany
    • 7.3.4. Prevalence of Symptoms associated with DGp in Germany
  • 7.4. France
    • 7.4.1. Total Prevalent Cases of Diabetic Gastroparesis in France
    • 7.4.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in France
    • 7.4.3. Prevalence of Diabetic Gastroparesis based on Gender in France
    • 7.4.4. Prevalence of Symptoms associated with DGp in France
  • 7.5. Italy
    • 7.5.1. Total Prevalent Cases of Diabetic Gastroparesis in Italy
    • 7.5.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Italy
    • 7.5.3. Prevalence of Diabetic Gastroparesis based on Gender in Italy
    • 7.5.4. Prevalence of Symptoms associated with DGp in Italy
  • 7.6. Spain
    • 7.6.1. Total Prevalent Cases of Diabetic Gastroparesis in Spain
    • 7.6.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Spain
    • 7.6.3. Prevalence of Diabetic Gastroparesis based on Gender in Spain
    • 7.6.4. Prevalence of Symptoms associated with DGp in Spain
  • 7.7. The United Kingdom
    • 7.7.1. Total Prevalent Cases of Diabetic Gastroparesis in the UK
    • 7.7.2. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in the UK
    • 7.7.3. Prevalence of Diabetic Gastroparesis based on Gender in the UK
    • 7.7.4. Prevalence of Symptoms associated with DGp in the UK
  • 7.8. Japan
    • 7.8.1. Assumptions and Rationale
    • 7.8.2. Total Prevalent Cases of Diabetic Gastroparesis in Japan
    • 7.8.3. Prevalence of Gastroparesis Associated with Types of Diabetes Mellitus in Japan
    • 7.8.4. Prevalence of Diabetic Gastroparesis based on Gender in Japan
    • 7.8.5. Prevalence of Symptoms associated with DGp in Japan

8. Treatment and Management of Diabetic Gastroparesis

  • 8.1. Consensus guidelines for the clinical management of diabetic gastroparesis
  • 8.2. Algorithm for the management of diabetic gastroparesis
  • 8.3. Patient Journey for Diabetic Gastroparesis

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight